Cytonus combines AI-driven drug discovery with its proprietary Cargocyte platform, a synthetic cell-like entity designed to deliver biologic drugs directly to targeted tissues, enhancing therapeutic efficacy and safety. This approach addresses the high failure rate of traditional drug delivery methods by minimizing systemic toxicity and improving localization of treatment at disease sites.
Funding
$15.7M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional drug delivery methods often result in systemic toxicity and fail to effectively target diseased tissues, leading to high failure rates in clinical trials and suboptimal therapeutic outcomes. This lack of precision limits the efficacy of even advanced precision medicines.
Solution
Cytonus is developing a novel drug delivery platform based on Cargocytes, enucleated cell-like entities engineered to deliver biologic drugs directly to targeted tissues. By combining AI-driven drug discovery with this targeted delivery system, Cytonus aims to enhance therapeutic efficacy while minimizing systemic toxicity. The Cargocyte platform enables localized production of biologic drugs at the disease site, improving drug safety and effectiveness. This approach addresses the limitations of conventional drug administration by ensuring that therapeutic payloads are delivered precisely where they are needed, reducing off-target effects and improving patient outcomes.
Target Audience
The primary target audience includes pharmaceutical companies and researchers focused on developing safer and more effective biologic drugs, as well as patients who could benefit from targeted therapies with reduced side effects.
Features
- Proprietary AI platform for rapid screening and design of highly predictable and successful therapeutics
- Cargocytes: enucleated, cell-like synthetic entities that enhance motility and migration to disease-specific sites
- Targeted delivery of biologic drugs directly to tissues, including tumors, the brain, and fibrotic tissues
- Intravenous administration with rapid homing and embedding of Cargocytes at the disease site
- Minimized systemic exposure and toxicity due to localized drug production